IRON Disc Medicine, Inc.
USHealthcareAs of 2026-07-10 16:00
Why IRON matters now
Disc Medicine, Inc. (IRON) is a US stock in Healthcare. The latest InvestLog snapshot shows $76.59 with -2.98% on the session and $2.93B in market capitalization; recent performance reads 1-month +10.49% and YTD -10.86%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-63.5M, and EPS of $-1.65. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -7.4%.
The latest indexable market news headline is "ROSEN, A LEADING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON" from Newsfile Corp.
Additional event context on this page matters because analyst consensus is Buy with a median target of $100.00; recent insider activity includes Yu Jonathan Yen-Wen filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.96
P/S
0.00
EV/EBITDA
-11.11
DCF Value
$2.31
FCF Yield
-7.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-36.9%
ROA
-32.2%
ROIC
-36.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-63.5M | $-1.65 |
| Q4 2025 | $0.00 | $-60.5M | $-1.64 |
| FY 2025 | $0.00 | $-212.2M | $-6.01 |
| Q3 2025 | $0.00 | $-62.3M | $-1.77 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$101.60
Target (Median)
$100.00
Target Range
$85.00 - $125.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.10
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.